FSGS Clinical Trial - Bortezomib for Treating Glomerular Diseases

Status Recruiting

Clinical Trial Summary

Bortezomib is a proteasome inhibitor that inhibits autoantibody production, and reduces podocyte damage and mesangial hyperplasia caused by NF-κB activation in the kidney. Literature has reported that bortezomib can achieve a complete response rate of up to 38% in the treatment of glomerular diseases, but its safety and effectiveness remain to be assessed for the Chinese demographic. This study attempts to explore a new treatment plan for glomerular disease by observing the therapeutic effect of bortezomib on glomerular disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05383547
Study type	Interventional
Source	Ruijin Hospital
Contact
Status	Recruiting
Phase	N/A
Start date	August 2, 2022
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05016323` - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.	Phase 2
Withdrawn	`NCT02433236` - Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy	Phase 2
Recruiting	`NCT02231125` - Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy	Phase 4
Completed	`NCT01502579` - An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data	N/A
Not yet recruiting	`NCT01203007` - Diet Intervention in Food Sensitive Patients With IgA Nephropathy	N/A
Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
Completed	`NCT00657059` - Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)	Phase 3
Recruiting	`NCT04684745` - Open-Label Extension Study of BION-1301 in IgA Nephropathy	Phase 2
Completed	`NCT03719443` - First in Human Study to Assess Safety of VIS649 in Healthy Subjects	Phase 1
Withdrawn	`NCT02052219` - BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy	Phase 3
Completed	`NCT02112838` - Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy	Phase 2
Completed	`NCT00767221` - Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study	Phase 2
Recruiting	`NCT04438603` - The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Terminated	`NCT04905212` - A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy	Phase 2
Terminated	`NCT04042623` - Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy	Phase 2
Recruiting	`NCT03633864` - Fecal Microbiota Transplantation for Refractory IgA Nephropathy	Phase 2
Recruiting	`NCT02954419` - IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Recruiting	`NCT03001947` - IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Completed	`NCT01224028` - A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients	Phase 2